[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346366-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346366-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","repression-of-prmt-activities-sensitize-human-homologous-recombination-proficient-ovarian-and-breast-cancer-cells-to-parp-inhibitor-treatment","Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment","","Therapeutic epigenetic modulation is evaluated in the clinic to sensitize homologous recombination (HR)-proficient tumors to PARP inhibitors. To broaden clinical applicability and discover more effective combinations, the study performs a drug screen that pairs PARP inhibitors with 74 epigenetic modulators across five major epigenetic enzyme classes. Type I PRMT and PRMT5 inhibitors show high combination efficacy and prioritization. PRMT inhibition increases PARP inhibitor–induced DNA damage in HR-proficient ovarian and breast cancer cells by downregulating DNA repair genes, BRCAness-associated pathways, and intrinsic innate immune responses. Large-scale TCGA and DepMap analyses further support PRMT1, PRMT4, and PRMT5 as oncology targets, with dual PRMT1/PRMT5 inhibition synergizing PARP responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/repression-of-prmt-activities-sensitize-human-homologous-recombination-proficient-ovarian-and-breast-cancer-cells-to-parp-inhibitor-treatment/346366/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/repression-of-prmt-activities-sensitize-human-homologous-recombination-proficient-ovarian-and-breast-cancer-cells-to-parp-inhibitor-treatment/346366.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the drug screening in this study?","Question",{"text":63,"@type":64},"The study aimed to broaden clinical applicability by identifying effective combination strategies pairing PARP inhibitors with epigenetic modulators across major enzyme classes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PRMT inhibition affect PARP inhibitor treatment in HR-proficient ovarian and breast cancer cells?",{"text":68,"@type":64},"PRMT inhibition significantly enhances PARP inhibitor–induced DNA damage by downregulating DNA damage repair genes and BRCAness-associated pathways, and by modulating intrinsic innate immune responses.",{"name":70,"@type":61,"acceptedAnswer":71},"Which PRMT targets are highlighted by additional genomic and functional dataset analyses?",{"text":72,"@type":64},"Large-scale analyses from TCGA and DepMap support PRMT1, PRMT4, and PRMT5 as promising therapeutic targets, and dual inhibition of PRMT1 and PRMT5 synergistically sensitizes tumors to PARP inhibitors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346366,1790158653,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","RESEARCH ARTICLE  \nRepression of PRMT activities sensitize human homologous recombination-  \n*For correspondence:  \nlinzhang@pennmedicine.upenn. edu (LZ);  \nxiaowenh@pennmedicine.upenn. edu (XH)  \n†These authors contributed equally to this work  \nPresent address:  \n‡GlaxoSmithKline, Collegeville, United States  \nCompeting interest: See page 23  \nFunding: See page 23  \nPreprint posted  \n21 May 2024  \nSent for Review  \n21 May 2024  \nReviewed preprint posted  \n17 July 2024  \nReviewed preprint revised  \n09 July 2025  \nReviewed preprint revised  \n26 September 2025  \nVersion of Record published  \n03 February 2026  \nReviewing Editor: Yongliang Yang, Shanghai University of Medicine and Health Sciences, China  \n Copyright Zhang, Xu et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.  \nproficient ovarian and breast cancer cells to PARP inhibitor treatment  \nYouyou Zhang1,2†‡, Mu Xu1†, Jiao Yuan1, Zhongyi Hu1, Junjie Jiang1, Yanrong Sun1, Jie Huang1, Yuxin Wang1, Bingwei Wang1, Jianfeng Shen1, Meixiao Long3, Yi Fan4,5, Kathleen T Montone6, Janos Tanyi2,4,7, Sarah H Kim2,4, Omid Tavana8, Robert H Vonderheide4, Ho Man Chan8, Susan Domchek4,9,10, Lin Zhang1,2,4*, Xiaowen Hu1,2*  \n1Center for Women’s Health and Reproductive Medicine, University of Pennsylvania, Philadelphia, United States; 2 Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, United States; 3 Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, United States; 4Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States; 5 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, United States; 6 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States; 7Center for Gynecologic Cancer Immunotherapies, University of Pennsylvania, Philadelphia, United States; 8 Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, United States; 9 Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, United States; 10 Basser Center for BRCA, University of Pennsylvania, Philadelphia, United States  \neLife Assessment  \nThis study presents a valuable and interesting finding that a combination of arginine methyltransferase inhibitors synergize with PARP inhibitors to eliminate ovarian and triple negative breast cancer cell lines in vitro and in vivo using preclinical mouse models. The data were collected and analyzed using solid and validated methodology and can be used as a starting point for the development of novel therapeutics. The work will be of broad interest to scientists working in the field of breast cancer and ovarian cancer.  \nAbstract Therapeutic epigenetic modulation is currently being evaluated in the clinic to sensitize homologous recombination (HR)-proficient tumors to PARP inhibitors. To broaden its clinical applicability and identify more effective combination strategies, we conducted a drug screen combining PARP inhibitors with 74 well-characterized epigenetic modulators targeting five major classes of epigenetic enzymes. Notably, both type I PRMT inhibitors and PRMT5 inhibitors scored highly in combination efficacy and clinical prioritization. PRMT inhibition significantly enhanced PARP inhibitor-induced DNA damage in human HR-proficient ovarian and breast cancer cells. Mechanistically, PRMT suppression downregulates DNA damage repair genes and BRCAness-associated pathways, while also modulating intrinsic innate immune responses within cancer cells. Integrative  \nZhang, Xu et al. eLife 2024;13:RP99225. DOI: [https://doi.org/10.7554/eLife.99225](https://doi.org/10.7554/eLife.99225) 1 of 31  \n Research article Cancer Biology  \nanalysis of large-scale genomic and functional datasets from TCGA and DepMap fur","cbCailFDigepJuPc","https://ap.wps.com/l/cbCailFDigepJuPc","pdf",13846997,31,"English","# Introduction\n# Abstract\n# eLife Assessment\n# Materials and methods (preclinical drug screen)\n# Mechanistic analysis and integrative datasets\n# Results and therapeutic implications","[{\"question\":\"What was the main goal of the drug screening in this study?\",\"answer\":\"The study aimed to broaden clinical applicability by identifying effective combination strategies pairing PARP inhibitors with epigenetic modulators across major enzyme classes.\"},{\"question\":\"How does PRMT inhibition affect PARP inhibitor treatment in HR-proficient ovarian and breast cancer cells?\",\"answer\":\"PRMT inhibition significantly enhances PARP inhibitor–induced DNA damage by downregulating DNA damage repair genes and BRCAness-associated pathways, and by modulating intrinsic innate immune responses.\"},{\"question\":\"Which PRMT targets are highlighted by additional genomic and functional dataset analyses?\",\"answer\":\"Large-scale analyses from TCGA and DepMap support PRMT1, PRMT4, and PRMT5 as promising therapeutic targets, and dual inhibition of PRMT1 and PRMT5 synergistically sensitizes tumors to PARP inhibitors.\"}]","Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment | PDF",1790061119,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f297419f07ffde4a4ad7b58e919dbfe3.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5882785038963b44e772ffbb506d5ba4.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd4de173eed2e66fa47c36dba1cbd42d.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce0c1768494acf1871f0e0f7a08e2980.webp",980,1268]